Genmab A/S GMAB 深 滬
已收盤 05-08 16:00:00 美东时间
26.43
-0.630
-2.33%
華盛通- 最 高26.76
- 今 開25.56
- 成交量 591.96万股
- 最 低 25.34
- 昨 收 27.06
- 總市值 1697.82万
- 52周最高 35.43
- 市盈率 靜 17.15
- 換手率 0.92%
- 52周最低 19.80
- 委 比 -43.07%
- 總股本 0.01亿
- 歷史最高 49.07
- 量 比 3.68
- 振 幅 5.25%
- 歷史最低 16.24
- 每 手 1
- 風險率 4.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Genmab Discloses Orbis as 5.08% Major Shareholder
Genmab ( ($GMAB) ) has provided an announcement. Genmab, the Copenhagen-based b...
05-09 06:10
Genmab shares are trading lower after the company reported mixed Q1 financial results.
Genmab shares are trading lower after the company reported mixed Q1 financial r...
05-08 19:40
LIVE MARKETS-Middle East peace worries return
LIVE MARKETS-Middle East peace worries return Adds blog post STOXX 600 down 0.8% All European sectors in the red U.S. futures higher Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com M
05-08 16:16
Genmab Affirms FY2026 Sales Guidance of $4.065B-$4.395B vs $4.300B Est
Genmab (NASDAQ:GMAB) affirms FY2026 sales outlook from $4.065 billion-$4.395 billion to $4.065 billion-$4.395 billion vs $4.300 billion estimate.
05-07 23:25
美股大行评级 | 潜在涨幅128.69%！Immunic获HC Wainwright & Co.升目标价至22美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immunic"买入"评级，目标价从5美元升至22美元；花旗：维持ServiceNow"买入"评级，目标价从154美元升至158美元
05-01 10:49
HC Wainwright & Co. Maintains Buy on Genmab, Lowers Price Target to $38
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and lowers the price target from $40 to $38.
04-30 18:22
期权扫描 | 财报大考在即，微软、亚马逊看涨单占比超六成；期权成交放量，市场预测SoFi 股价波动10.55%；现潜伏信号，资金押注英特尔看涨110美元
财报大考在即，微软、亚马逊看涨期权占比超6成；期权成交放量，市场预测SoFi 股价波动10.55%；现潜伏信号，资金押注英特尔看涨110美元>>
04-29 17:16
全球首款BCMA ADC中国上市！撞上5款竞品，还卖得动吗？
（来源：求实药社） 2026年4月17日，国家药监局官网显示，葛兰素史克（GSK）的玛贝兰妥单抗（Belantamab mafodotin）在国内获批上市，与硼...
04-20 12:19
Genmab confirms $3.96B DARZALEX sales in Q1, led by U.S. demand
Genmab (GMAB) said that worldwide net sales of its multiple myeloma therapy DARZALEX (daratumumab) as reported by Johnson & Johnson (JNJ), totaled $3.96B in Q1. U.S. sales came in at $2.208B, while $1...
04-14 20:01
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, achieved a confirmed objective response rate of 47.9% in centrally tested patients with HER2-expressing, recurrent endometrial cancer, and a median progression-free survival of 8.1 months. The Phase 2 trial demonstrated clinically meaningful antitumor activity across all HER2 expression levels, with manageable safety profiles. The results support its potential as a ...
04-11 11:00
